Allison Kempe1,2, Mandy A Allison3,2, Jessica R MacNeil4, Sean T O'Leary3,2, Lori A Crane3,5, Brenda L Beaty3, Laura P Hurley3,6, Michaela Brtnikova3,2, Megan C Lindley4, Alison P Albert4. 1. Adult and Child Consortium for Health Outcomes Research and Delivery Science, School of Medicine, allison.kempe@childrenscolorado.org. 2. Department of Pediatrics, Anschutz Medical Campus, and. 3. Adult and Child Consortium for Health Outcomes Research and Delivery Science, School of Medicine. 4. National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; and. 5. Department of Community and Behavioral Health, Colorado School of Public Health, University of Colorado and Children's Hospital Colorado, Aurora, Colorado. 6. Division of General Internal Medicine, Denver Health, Denver, Colorado.
Abstract
: media-1vid110.1542/5799875076001PEDS-VA_2018-0344Video Abstract BACKGROUND AND OBJECTIVES: In 2015, the Advisory Committee on Immunization Practices recommended that 16- to 23-year-olds may be vaccinated with the serogroup B meningococcal (MenB) vaccine on the basis of individual clinical decision-making (Category B). We assessed the following among US pediatricians and family physicians (FPs): (1) practices regarding MenB vaccine delivery, (2) factors influencing a decision to recommend the MenB vaccine, and (3) factors associated with discussing the MenB vaccine. METHODS: We surveyed a nationally representative sample of pediatricians and FPs via e-mail and Internet from October 2016 to December 2016. RESULTS: The response rate was 72% (660 of 916). During routine visits, 51% of pediatricians and 31% of FPs reported always or often discussing MenB vaccine. Among those who discussed often or always, 91% recommended vaccination; among those who never or rarely discussed, 11% recommended. We found that 73% of pediatricians and 41% of FPs currently administered the MenB vaccine. Although many providers reported not knowing about factors influencing recommendation decisions, MenB disease outbreaks (89%), disease incidence (62%), and effectiveness (52%), safety (48%), and duration of protection of MenB vaccine (39%) increased the likelihood of recommendation, whereas the Category B recommendation (45%) decreased likelihood. Those somewhat or not at all aware of the MenB vaccine (risk ratio 0.32 [95% confidence interval 0.25-0.41]) and those practicing in a health maintenance organization (0.39 [0.18-0.87]) were less likely, whereas those aware of disease outbreaks in their state (1.25 [1.08-1.45]) were more likely to discuss MenB vaccine. CONCLUSIONS: Primary care physicians have significant gaps in knowledge about MenB disease and the MenB vaccine, and this appears to be a major driver of the decision not to discuss the vaccines.
: media-1vid110.1542/5799875076001PEDS-VA_2018-0344Video Abstract BACKGROUND AND OBJECTIVES: In 2015, the Advisory Committee on Immunization Practices recommended that 16- to 23-year-olds may be vaccinated with the serogroup B meningococcal (MenB) vaccine on the basis of individual clinical decision-making (Category B). We assessed the following among US pediatricians and family physicians (FPs): (1) practices regarding MenB vaccine delivery, (2) factors influencing a decision to recommend the MenB vaccine, and (3) factors associated with discussing the MenB vaccine. METHODS: We surveyed a nationally representative sample of pediatricians and FPs via e-mail and Internet from October 2016 to December 2016. RESULTS: The response rate was 72% (660 of 916). During routine visits, 51% of pediatricians and 31% of FPs reported always or often discussing MenB vaccine. Among those who discussed often or always, 91% recommended vaccination; among those who never or rarely discussed, 11% recommended. We found that 73% of pediatricians and 41% of FPs currently administered the MenB vaccine. Although many providers reported not knowing about factors influencing recommendation decisions, MenB disease outbreaks (89%), disease incidence (62%), and effectiveness (52%), safety (48%), and duration of protection of MenB vaccine (39%) increased the likelihood of recommendation, whereas the Category B recommendation (45%) decreased likelihood. Those somewhat or not at all aware of the MenB vaccine (risk ratio 0.32 [95% confidence interval 0.25-0.41]) and those practicing in a health maintenance organization (0.39 [0.18-0.87]) were less likely, whereas those aware of disease outbreaks in their state (1.25 [1.08-1.45]) were more likely to discuss MenB vaccine. CONCLUSIONS: Primary care physicians have significant gaps in knowledge about MenB disease and the MenB vaccine, and this appears to be a major driver of the decision not to discuss the vaccines.
Authors: Sean T O'Leary; Umesh D Parashar; Lori A Crane; Mandy A Allison; Shannon Stokley; Brenda L Beaty; Michaela Brtnikova; Laura P Hurley; Allison Kempe Journal: Am J Prev Med Date: 2013-01 Impact factor: 5.043
Authors: Mandy A Allison; Laura P Hurley; Lauri Markowitz; Lori A Crane; Michaela Brtnikova; Brenda L Beaty; Megan Snow; Janine Cory; Shannon Stokley; Jill Roark; Allison Kempe Journal: Pediatrics Date: 2016-01-04 Impact factor: 7.124
Authors: Stanley J Schaffer; Peter G Szilagyi; Laura P Shone; Sandra J Ambrose; M Katherine Dunn; Richard D Barth; Kathryn Edwards; Geoffrey A Weinberg; Sharon Balter; Benjamin Schwartz Journal: Pediatrics Date: 2002-12 Impact factor: 7.124
Authors: Mandy A Allison; Amanda C Cohn; Shannon Stokley; Lori A Crane; Sean T O'Leary; Laura P Hurley; Christine I Babbel; Fran Dong; Claire Gahm; Jonathan L Temte; Allison Kempe Journal: Am J Prev Med Date: 2011-12 Impact factor: 5.043
Authors: Maria Elena Santolaya; Miguel O'Ryan; María Teresa Valenzuela; Valeria Prado; Rodrigo F Vergara; Alma Muñoz; Daniela Toneatto; Gabriela Graña; Huajun Wang; Peter M Dull Journal: Hum Vaccin Immunother Date: 2013-06-28 Impact factor: 3.452
Authors: Allison Kempe; Sean T O'Leary; Lauri E Markowitz; Lori A Crane; Laura P Hurley; Michaela Brtnikova; Brenda L Beaty; Elissa Meites; Shannon Stokley; Megan C Lindley Journal: Pediatrics Date: 2019-09-16 Impact factor: 7.124
Authors: Mallory K Ellingson; Robert A Bednarczyk; Sean T O'Leary; Jason L Schwartz; Eugene D Shapiro; Linda M Niccolai Journal: J Behav Med Date: 2022-02-22
Authors: Eric Richardson; Kathleen A Ryan; Robert M Lawrence; Christopher A Harle; Alyson Young; Melvin D Livingston; Amit Rawal; Stephanie A S Staras Journal: J Community Health Date: 2021-01-02